Drug Trial Radar · NCT05069740
Endometriosis and Microvascular Dysfunction: Role of Inflammation
Last checked: Nov 20, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Jan 1, 2022
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Penn State UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 6, 2021
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Single (investigator)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to better understand the underlying mechanisms associated with elevated cardiovascular disease risk in women with endometriosis, and to measure the effectiveness of emerging endometriosis treatments on outcomes specific to cardiovascular dysfunction. Epidemiologic data demonstrate a clear association between endometriosis, reproductive risk factors, inflammation and cardiovascular (CV) risk. Circulating factors, low-density lipoprotein (LDL) and oxidized LDL (oxLDL), are two of many biomarkers of cardiovascular and inflammatory disease of endometriosis. An important signaling mechanism through which circulating LDL and oxLDL act is the lectin-like oxidized LDL receptor (LOX-1). LOX-1 signal transduction functionally results in pronounced endothelial dysfunction, a hallmark of CV. The investigators hypothesis that one factor mediating the elevated risk of cardiovascular disease in endometriosis is systemic inflammation and activation of LOX-1 receptor mechanisms.
Conditions
- Endometriosis
Interventions
Salsalate PillDrug
Salsalate acts as an NFkB inhibitor to reduce systemic inflammation
PlaceboDrug
Placebo for the salsalate intervention
Primary outcomes
What the sponsor says the trial is designed to measure.
- cutaneous vascular conductanceTime frame: 5 days after treatment
- brachial artery diameter and blood flow velocityTime frame: 5 days after treatment
- Sera LOX-1 protein expressionTime frame: 5 days after treatment
- Biopsy LOX-1 protein expressionTime frame: 5 days after treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Pennsylvania State University
University Park, Pennsylvania · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.